TWM531276U - Grain structure of antrodia camphorata and ganoderma lucidum composition - Google Patents

Description

靈樟芝顆粒結構Lingzhizhi particle structure

本新型係關於醫藥組合物之技術領域，尤指一種靈樟芝顆粒結構。 The present invention relates to the technical field of pharmaceutical compositions, in particular to a Lingzhizhi particle structure.

腎臟位於人體腰部腹膜腔的後方，包括左腎與右腎；其中，每個腎皆含有100萬個腎元，且每個腎元係由腎絲球、鮑氏囊與腎小管所構成。腎臟在人類的循環與***作用中扮演很重要的角色，其具備了以下功能：(1)排除身體內的廢物、藥物；(2)維持身體內水份、酸鹼值、與電解質的平衡；(3)產生血管加壓素以控制血壓；(4)產生維他命D以控制鈣質吸收與骨質發育；(5)產生紅血球生血素以維持紅血球的正常代謝。 The kidney is located behind the peritoneal cavity of the human waist, including the left kidney and the right kidney. Each kidney contains 1 million kidneys, and each kidney is composed of a kidney spheroid, a Bowman's capsule and a renal tubule. The kidney plays an important role in human circulation and excretion. It has the following functions: (1) to eliminate waste and drugs in the body; (2) to maintain the balance of water, pH, and electrolytes in the body; (3) vasopressin is produced to control blood pressure; (4) vitamin D is produced to control calcium absorption and bone development; (5) erythrocyte hemoglobin is produced to maintain normal metabolism of red blood cells.

由於腎臟為人體之中所不可或缺的器官，因此，當腎功能開始發生異常之時，除了會導致人體內的廢物、藥物與代謝產物無法正常排出體以外，腎的調節功效也將會大幅降低；更嚴重者，當腎功能嚴 重異常時，還會引發***而危及患者性命。副腎上腺皮質激素，俗稱類固醇，為目前治療嚴重蛋白尿引發的腎絲球炎及腎病症候群所經常使用處方藥。然而，即使類固醇能夠有效治療腎絲球炎，但卻必須以高劑量的類固醇持續用藥1至4個月以後，才會顯現出治療效果。此外，長期服用類固醇藥物容易產生血糖上升、月亮臉、水牛肩、情緒不穩定、腎上腺賀爾蒙異常等副作用。 Because the kidney is an indispensable organ in the human body, when the kidney function begins to abnormal, in addition to the waste, drugs and metabolites in the human body can not be properly discharged, the renal regulation effect will be greatly Reduced; more severe, when the kidneys function When the abnormality is abnormal, it also causes uremia and endangers the patient's life. Para-adrenal cortex hormone, commonly known as steroids, is often used as a prescription for the treatment of severe retinoin-induced glomerulonephritis and renal disease. However, even if steroids are effective in treating glomerulonephritis, they must be treated with high doses of steroids for 1 to 4 months before they appear to have a therapeutic effect. In addition, long-term use of steroid drugs is prone to side effects such as rising blood sugar, moon face, buffalo shoulder, emotional instability, and abnormal adrenal hormones.

另一方面，眾所周知的是，腎癌是泌尿系統中惡性度較高的腫瘤，並可細分為腎原細胞癌、腎盂癌、腎腺癌。其中，腎臟腺癌是由腎小管的上皮細胞病變所衍生的癌症，主要發生於成年人。可怕的是，腎臟癌細胞初期發展緩慢，所以並不會顯現早期症狀，當腫瘤擴散到鄰近的器官或大部份的腎組織被侵犯時，才會引起疼痛和血尿的症狀。腎臟癌的治療主要可分為外科手術法、化學療法、放射治療、及免疫療法。近年來，醫生通常只會以外科手術摘除帶有腫瘤部份之腎臟組織並接著搭配化學療法或免疫療法進行後續處理，希望藉此方式使患者能夠保留較多的腎臟功能。然而，臨床數據顯示，肇因於腫瘤血管的嚴重增生，導致腎細胞癌(renal cell carcinoma，RCC)對化學藥物的反應並不顯著。雖然可以改採標靶藥物(例如Sutent(紓癌特)與Nexavar(蕾莎瓦))來抑制腎細胞癌的癌細胞新生，然而前者會衍生出手足症與皮膚增生等副作用，且後者會導致腹瀉、疲勞、脫皮等副作用。 On the other hand, it is well known that kidney cancer is a tumor with a high degree of malignancy in the urinary system and can be subdivided into renal cell carcinoma, renal pelvic cancer, and renal adenocarcinoma. Among them, renal adenocarcinoma is a cancer caused by epithelial cell lesions of the renal tubules, mainly in adults. The terrible thing is that kidney cancer cells develop slowly in the early stage, so they don't show early symptoms. When the tumor spreads to neighboring organs or most of the kidney tissue is invaded, it will cause pain and hematuria. The treatment of kidney cancer can be mainly divided into surgery, chemotherapy, radiation therapy, and immunotherapy. In recent years, doctors usually only surgically remove the kidney tissue with the tumor part and then follow up with chemotherapy or immunotherapy, in the hope that the patient can retain more kidney function. However, clinical data show that due to the severe proliferation of tumor blood vessels, renal cell carcinoma (RCC) does not respond significantly to chemical drugs. Although target drugs (such as Sutent and Nexavar) can be used to inhibit cancer cell growth in renal cell carcinoma, the former may cause side effects such as hand-foot disease and skin hyperplasia, and the latter may cause Side effects such as diarrhea, fatigue, and peeling.

不同習知技術係以高劑量的類固醇持續用藥1至4個月才能夠顯著改善腎絲球炎等腎病症候群，靈樟芝組合物只需要以7mg/mL 的低劑量對患有嚴重腎衰竭的病人進行20天左右的治療便能夠顯著改善腎功能異常的狀況。同時，靈樟芝組合物已經藉由細胞生物實驗證實了的確具有抑制腎癌細胞增生之功效。有鑑於此，本案之創作人係極力加以研究新型，而終於研發完成本新型之一種靈樟芝顆粒結構。 Different conventional techniques can significantly improve kidney disease such as renal glomerulosis by using high-dose steroids for 1 to 4 months. The Lingzhizhi composition only needs 7mg/mL. Low doses of patients with severe renal failure can significantly improve renal dysfunction after treatment for about 20 days. At the same time, the Lingzhizhi composition has been confirmed by cell biological experiments to have the effect of inhibiting the proliferation of renal cancer cells. In view of this, the creators of this case tried to study the new type, and finally developed a novel Lingzhi granule structure.

本新型之主要目的，在於提供一種靈樟芝顆粒結構，係由一水溶性保護層、一增塑性基質、一牛樟芝萃出物、一靈芝萃出物、以及一輔酵素所構成。此靈樟芝顆粒結構種係具備著多項優點，例如：體積小、重量輕、易於攜帶、準確的功效成分含量。並且，此靈樟芝顆粒結構可透過舌下吸收，以達迅速溶解及快速吸收之效，並同時使得靈芝與樟芝的功效成分迅速地進入血液循環系統，大幅度提昇靈芝與樟芝的生體可用率。另一方面，藉由水溶性保護層以及防潮保護層包覆該靈樟芝精華核心的結構方式，於服用所述的靈樟芝顆粒結構之後，係能夠於服用者的體內達到持續釋放保健功效之成分以及分階釋放複方成分物質之效果，進而能夠避免複方成分交互作用。 The main purpose of the present invention is to provide a structure of Lingzhizhi granules, which is composed of a water-soluble protective layer, a plasticized matrix, an extract of Antrodia camphorata, a Ganoderma lucidum extract, and a coenzyme. This Lingzhi granule structure has many advantages, such as small size, light weight, easy to carry, and accurate functional ingredient content. Moreover, the structure of the Lingzhizhi granules can be absorbed through the tongue to achieve rapid dissolution and rapid absorption, and at the same time, the functional ingredients of Ganoderma lucidum and Antrodia camphorata rapidly enter the blood circulation system, thereby greatly improving the growth of Ganoderma lucidum and Antrodia camphorata. Body availability. On the other hand, the structure of the core of the Lingzhizhi essence is coated by the water-soluble protective layer and the moisture-proof protective layer, and after taking the structure of the Lingzhizhi granules, the sustained release health care effect can be achieved in the body of the user. The composition and the effect of releasing the compound components in stages can further avoid the interaction of the compound components.

為了達成上述本新型之主要目的，本案之創作人係提供一種靈樟芝顆粒結構的一第一實施例，係包括：一水靈樟芝精華核心，其於所述靈樟芝顆粒結構之中的重量百分比係介於12.8wt%至55.7wt%之間； 一水溶性保護層，用以包覆於該靈樟芝精華核心；並且，該水溶性保護層於所述靈樟芝顆粒結構之中的重量百分比係介於40wt%至60wt%之間；以及一防潮保護層，用以包覆於該水溶性保護層；並且，該防潮保護層於所述靈樟芝顆粒結構之中的重量百分比係介於40wt%至60wt%之間。 In order to achieve the above-mentioned main purpose of the present invention, the creator of the present invention provides a first embodiment of the structure of the Lingzhizhi granules, comprising: a core of the genus Antrodia camphorata, which is in the structure of the lingzhi granules. The weight percentage is between 12.8 wt% and 55.7 wt%; a water-soluble protective layer for coating the core of the Lingzhi extract; and the weight percentage of the water-soluble protective layer in the structure of the Lingzhi granule is between 40% by weight and 60% by weight; a moisture-proof protective layer for coating the water-soluble protective layer; and the moisture-proof protective layer is between 40% by weight and 60% by weight in the structure of the Lingzhi granule structure.

於上述之靈樟芝顆粒結構的第一實施例中，所述水溶性保護層係選自於包含於下列群組中的任一者：聚乙二醇(polyethylene glycol,PEG)、聚乙烯吡咯烷酮(polyvinylpyrrolidone,PVP)、聚氧乙烯單硬脂酸脂(polyoxyethylene monostearate,S40)、硬脂酸鈉、甘油、明膠、尿素、泊洛沙姆(poloxamer)、與上述任兩者或兩者以上的混合物。 In a first embodiment of the above-described aglycone particle structure, the water-soluble protective layer is selected from any one of the group consisting of polyethylene glycol (PEG), polyvinylpyrrolidone (polyvinylpyrrolidone, PVP), polyoxyethylene monostearate (S40), sodium stearate, glycerin, gelatin, urea, poloxamer, and any two or more of the above mixture.

並且，於上述之靈樟芝顆粒結構的第一實施例中，所述防潮保護層係選自於包含於下列群組中的任一者：預膠化澱粉、羧甲基澱粉、甲基纖維素、羧甲基纖維素鈉、羥丙基甲基纖維素、***膠、海藻酸、糊精、環糊精、瓊脂、乳糖、與上述任兩者或兩者以上的混合物。 Moreover, in the first embodiment of the above-described aglycone particle structure, the moisture-proof protective layer is selected from any one of the group consisting of pregelatinized starch, carboxymethyl starch, and methyl fiber. , sodium carboxymethylcellulose, hydroxypropylmethylcellulose, gum arabic, alginic acid, dextrin, cyclodextrin, agar, lactose, a mixture of any two or more of the foregoing.

另外，於上述之靈樟芝顆粒結構的第一實施例中，所述靈樟芝精華核心係包含一牛樟芝萃出物、一靈芝萃出物與至少一輔酵素。 In addition, in the first embodiment of the above-described Lingzhizhi granule structure, the core of the Lingzhizhi extract comprises a extract of Antrodia camphorata, a extract of Ganoderma lucidum and at least one coenzyme.

並且，為了達成上述本新型之主要目的，本案之創作人係提供一種靈樟芝顆粒結構的一第二實施例，其中，該靈樟芝顆粒結構的 第二實施例係為由一牛樟芝萃出物、一靈芝萃出物、以及至少一輔酵素所構成的一均質體。 Moreover, in order to achieve the above-mentioned main purpose of the present invention, the creator of the present invention provides a second embodiment of the structure of the Lingzhizhi particle structure, wherein the structure of the Lingzhizhi particle structure The second embodiment is a homogenate composed of an extract of Antrodia camphorata, a extract of Ganoderma lucidum, and at least one coenzyme.

於上述之靈樟芝顆粒結構的第二實施例中，所述均質體的外型可為下列任一種：圓形錠型、橢圓形錠型、三角形錠型、四角形錠型、蜆狀錠型、與中空圓形錠型。 In the second embodiment of the above-described aglycone particle structure, the shape of the homogenous body may be any of the following: a circular ingot type, an elliptical ingot type, a triangular ingot type, a quadrangular ingot type, and a beryllium ingot type. With a hollow circular ingot type.

並且，於上述之靈樟芝顆粒結構的第二實施例中，所述均質體可進一步被磨成粉末狀，並以一容置體裝盛之；並且，該容置體可為藥粉包裝袋、藥罐、或膠囊。 Moreover, in the second embodiment of the above-described aglycone particle structure, the homogenous body may be further ground into a powder and filled in a receiving body; and the containing body may be a powder bag. , medicine cans, or capsules.

<本新型> <This new type>

1‧‧‧靈樟芝顆粒結構 1‧‧‧ Lingzhizhi particle structure

11‧‧‧靈樟芝精華核心 11‧‧‧ Lingzhizhi essence core

12‧‧‧水溶性保護層 12‧‧‧Water-soluble protective layer

13‧‧‧防潮保護層 13‧‧‧ moisture protection layer

111‧‧‧牛樟芝萃出物 111‧‧‧ Astragalus extract

112‧‧‧靈芝萃出物 112‧‧‧Ganoderma lucidum extract

2‧‧‧口服錠 2‧‧‧ Oral ingot

4‧‧‧藥粉包裝袋 4‧‧‧ powder bag

3‧‧‧杯子 3‧‧‧ cup

圖1係顯示本新型之靈樟芝顆粒結構的立體結構的部份剖面圖；圖2係顯示本新型之靈樟芝顆粒結構的側視剖面圖；圖3A至圖3D係顯示本新型之靈樟芝顆粒結構的錠型實施態樣；圖4係顯示粉末狀之靈樟芝顆粒結構的示意立體圖；以及圖5係粉末狀之靈樟芝顆粒結構的使用示意圖。 1 is a partial cross-sectional view showing the three-dimensional structure of the structure of the present invention; FIG. 2 is a side cross-sectional view showing the structure of the novel Lingzhizhi particle; FIG. 3A to FIG. 3D are showing the novel spirit. FIG. 4 is a schematic perspective view showing the structure of the powdered Ganoderma lucidum granules; and FIG. 5 is a schematic view showing the use of the granule structure of the granules of Ganoderma lucidum.

為了能夠更清楚地描述本新型所提出之一種靈樟芝顆粒結構，以下將配合圖式，詳盡說明本新型創作之較佳實施例。 In order to more clearly describe the structure of a Lingzhizhi particle proposed by the present invention, a preferred embodiment of the novel creation will be described in detail below with reference to the drawings.

第一實施例 First embodiment

請參閱圖1與圖2，係分別為本新型之靈樟芝顆粒結構的立體結構的部份剖面圖以及側面剖面圖。本新型所提出的一種靈樟芝顆粒結構1係為一滴丸(dropping pill)結構，其中，該滴丸結構的粒徑範圍約為2.0~3.5mm，且其重量約為18~25mg/pill之間。如圖所示，此靈樟芝顆粒結構1係由一靈樟芝精華核心11、一水溶性保護層12以及一防潮保護層13所構成。其中，靈樟芝精華核心11係包含一牛樟芝萃出物111、一靈芝萃出物112以及至少一種輔酵素；並且，該靈樟芝精華核心11於所述靈樟芝顆粒結構1之中的重量百分比係介於12.8wt%至55.7wt%之間。 Referring to FIG. 1 and FIG. 2, a partial cross-sectional view and a side cross-sectional view of a three-dimensional structure of the novel Lingzhizhi particle structure are respectively shown. The Lingzhizhi granule structure 1 proposed by the present invention is a dropping pill structure, wherein the droplet structure has a particle size ranging from about 2.0 to 3.5 mm, and the weight thereof is about 18 to 25 mg/pill. between. As shown in the figure, the Lingzhi granule structure 1 is composed of a Lingzhi essence core 11, a water-soluble protective layer 12, and a moisture-proof protective layer 13. Wherein, the core 11 of the Lingzhi extract comprises a bovine agar extract 111, a ganoderma extract 112 and at least one coenzyme; and the core of the Lingzhi extract is in the structure 1 of the Lingzhizhi The weight percentage is between 12.8 wt% and 55.7 wt%.

承上述，該水溶性保護層12係用以包覆於該靈樟芝精華核心11；並且，該水溶性保護層12於所述靈樟芝顆粒結構1之中的重量百分比係介於40wt%至60wt%之間。於本新型創作中，所述水溶性保護層12可以是包含於下列群組之中的任一者：選自於包含於下列群組中的任一者：聚乙二醇(polyethylene glycol,PEG)、聚乙烯吡咯烷酮(polyvinylpyrrolidone,PVP)、聚氧乙烯單硬脂酸脂(polyoxyethylene monostearate,S40)、硬脂酸鈉、甘油、明膠、尿素、泊洛沙姆(poloxamer)、與上述任兩者或兩者以上的混合物。 In the above, the water-soluble protective layer 12 is used to coat the core of the Lingzhi extract; and the weight percentage of the water-soluble protective layer 12 in the Lingzhi grain structure 1 is 40% by weight. Between 60% by weight. In the novel creation, the water-soluble protective layer 12 may be included in any one of the following groups: selected from any of the following groups: polyethylene glycol (PEG) ), polyvinylpyrrolidone (PVP), polyoxyethylene monostearate (S40), sodium stearate, glycerin, gelatin, urea, poloxamer, and both Or a mixture of two or more.

另一方面，該防潮保護層13係為一增塑性基質，用以包覆於該水溶性保護層12；並且，該防潮保護層13於所述靈樟芝顆粒結構1之中的重量百分比係介於40wt%至60wt%之間。於本新型創作中，所述水溶性保護層12可以是包含於下列群組之中的任一者：選自於包含於下列群組中的任一者：預膠化澱粉、羧甲基澱粉、甲基纖維素、 羧甲基纖維素鈉、羥丙基甲基纖維素、***膠、海藻酸、糊精、環糊精、瓊脂、乳糖、與上述任兩者或兩者以上的混合物。 On the other hand, the moisture-proof protective layer 13 is a plasticizing matrix for coating the water-soluble protective layer 12; and the weight percentage of the moisture-proof protective layer 13 in the Lingzhizhi grain structure 1 is Between 40% and 60% by weight. In the novel creation, the water-soluble protective layer 12 may be included in any one of the following groups: selected from any of the following groups: pregelatinized starch, carboxymethyl starch ,Methylcellulose, Sodium carboxymethylcellulose, hydroxypropylmethylcellulose, gum arabic, alginic acid, dextrin, cyclodextrin, agar, lactose, a mixture of any two or more of the foregoing.

必須特別說明的是，該牛樟芝萃出物111係至少包含三萜類化合物(triterpenoids)與腺苷(Adenosine)等功效性成分，並且該靈芝萃出物112至少包含多醣體(polysaccharide)等功效性成分。另一方面，所述輔酵素係包含維他命B群與輔酶Q10。請參閱下表(一)，係記載了本新型之靈樟芝顆粒結構1所包含的功能性成分與對應的藥理功效。 It should be particularly noted that the extract of A. angustifolia 111 contains at least functional ingredients such as triterpenoids and adenosine, and the ganoderma extract 112 contains at least polysaccharides and the like. ingredient. In another aspect, the coenzyme comprises a vitamin B group and a coenzyme Q10. Please refer to the following table (1), which describes the functional ingredients and corresponding pharmacological effects contained in the structure 1 of Lingzhizhi Granules of the present invention.

第二實施例 Second embodiment

上述已說明了本新型之靈樟芝顆粒結構1的第一實施例，然而，對應於醫藥組合物可能會有多種不同的形態及服用方式，接下來將介紹本新型之靈樟芝顆粒結構1的第二實施例。請參閱圖3A至圖3D，係顯示本新型之靈樟芝顆粒結構的錠型實施態樣。本新型之靈樟芝顆粒結構1也可以是由牛樟芝萃出物111、靈芝萃出物112、與至少一輔酵素所構成的一均質體。並且，如圖3A至圖3D所示，該均質體可透過打錠機加工成圓形錠型、四角形錠型、三角形錠型、或蜆狀 錠型之口服錠2。此外，亦可在口服錠2的外部額外地形成一外套層，亦即俗稱的膜衣。其中，該外套層可以是包含於下列群組之中的任一者：糖精鈉、砂糖、葡萄糖、澱粉糖漿、右旋糖、果糖、甘油、異麥芽酮糖醇、乳糖醇、乳糖、麥芽糖醇、麥芽糖、甘露糖醇、山梨糖醇、蔗糖、塔格糖、海藻糖、木糖醇、阿力甜、阿斯巴甜、乙醯磺胺酸鉀、環拉酸、環拉酸鹽、新橘皮苷二氫查酮、祝馬丁、糖精、糖精鹽、蔗糖素其中之一或其組合。並且，如圖3C所示所述均質體的表面可以進一步地刻有至少一個刻痕。 The first embodiment of the novel Anthraquinone granule structure 1 has been described above. However, there may be many different forms and dosage forms corresponding to the pharmaceutical composition, and the novel Lingzhizhi granule structure 1 will be described next. The second embodiment. Referring to FIG. 3A to FIG. 3D, an ingot type embodiment of the novel Lingzhizhi particle structure is shown. The novel Lingzhi granule structure 1 may also be a homogenate composed of Antrodia camphorata extract 111, Ganoderma lucidum extract 112, and at least one coenzyme. And, as shown in FIG. 3A to FIG. 3D, the homogeneous body can be processed into a circular ingot shape, a quadrangular ingot shape, a triangular ingot shape, or a braided shape through a tableting machine. Ingot type oral ingot 2. Further, an outer layer, that is, a film coat, which is commonly referred to as a film coat, may be additionally formed on the outside of the oral ingot 2. Wherein, the outer layer may be included in any one of the following groups: sodium saccharin, sugar, glucose, starch syrup, dextrose, fructose, glycerol, isomalt, lactitol, lactose, maltose Alcohol, maltose, mannitol, sorbitol, sucrose, tagatose, trehalose, xylitol, alitame, aspartame, potassium sulfamate, cyclamate, cyclamate, new One of or a combination of hesperidin dihydrochalcone, Zhu Martin, saccharin, saccharin salt, sucralose. Also, the surface of the homogeneous body may be further engraved with at least one score as shown in FIG. 3C.

再者，於實際生產時，亦可將本新型之靈樟芝顆粒結構1的均質體填充入磨粉機中再被磨製成粉末。請參閱圖4，係顯示粉末狀之靈樟芝顆粒結構的示意立體圖；並且，請同時參閱圖5，係顯示粉末狀之靈樟芝顆粒結構的使用示意圖。如圖4所示，被磨製成粉末狀的靈樟芝顆粒結構1係能夠以類似藥粉包裝袋4的一容置體裝盛之。如圖5所示，如此一來，服用該靈樟芝顆粒結構1之時，只需將該藥粉包裝袋4撕開，便可直接口腔攝食，或是將藥粉倒入裝有一溶液的杯子3後直接飲用。必須補充說明的是，所述容置體並不限於藥袋，亦可以是藥罐、膠囊、脂質載體、或複合型奈米脂質載體。 Furthermore, in actual production, the homogeneous body of the novel Lingzhizhi particle structure 1 can also be filled into a mill and then ground into a powder. Referring to Fig. 4, there is shown a schematic perspective view showing the structure of the powdered Ganoderma lucidum granules; and, referring to Fig. 5, a schematic view showing the use of the granule structure of the granules of Ganoderma lucidum. As shown in Fig. 4, the Lingzhizhi granule structure 1 which is ground into a powder can be contained in a container similar to the powder packaging bag 4. As shown in FIG. 5, when the structure 1 of the Lingzhizhi granule is taken, the powder packaging bag 4 can be directly torn, and the powder can be directly ingested or poured into a cup containing a solution. Drink directly afterwards. It should be added that the container is not limited to a medicine bag, and may be a medicine can, a capsule, a lipid carrier, or a complex type nanolipid carrier.

如此，上述係已完整且清楚地說明本新型之靈樟芝顆粒結構1，經由上述，可以得知本新型係具有下列之優點： Thus, the above-mentioned system has completely and clearly explained the structure 1 of the Lingzhizhi granule of the present invention. From the above, it can be known that the novel system has the following advantages:

(1)本新型所提供的靈樟芝顆粒結構1係由一水溶性保護層12、一增塑性基質(即，防潮保護層13)、一牛樟芝萃出物111、一靈芝萃出物112、以及一輔酵素所構成。此靈樟芝顆粒結構1種係具備 著多項優點，例如：體積小、重量輕、易於攜帶、準確的功效成分含量。並且，此靈樟芝顆粒結構1可透過舌下吸收，以達迅速溶解及快速吸收之效，並同時使得靈芝與樟芝的功效成分迅速地進入血液循環系統，大幅度提昇靈芝與樟芝的生體可用率。另一方面，藉由水溶性保護層12以及防潮保護層包覆該靈樟芝精華核心11的結構方式，於服用所述的靈樟芝顆粒結構1之後，係能夠於服用者的體內達到持續釋放(具保健功效之成分)及分階釋放複方成分物質之效果，進而能夠避免複方成分交互作用。 (1) The Lingzhizhi granule structure 1 provided by the present invention comprises a water-soluble protective layer 12, a plasticized matrix (i.e., moisture-proof protective layer 13), a burdock extract 111, and a ganoderma lucidum extract 112. And a coenzyme. This Lingzhizhi particle structure has one type of A number of advantages, such as: small size, light weight, easy to carry, accurate functional ingredient content. Moreover, the structure of the Lingzhi granules can be absorbed through the tongue to achieve rapid dissolution and rapid absorption, and at the same time, the functional components of Ganoderma lucidum and Antrodia can rapidly enter the blood circulation system, and greatly enhance the Ganoderma lucidum and Antrodia camphorata. Bioavailability. On the other hand, the structure of the Lingzhizhi essence core 11 is coated by the water-soluble protective layer 12 and the moisture-proof protective layer, and after taking the Lingzhizhi granule structure 1, the body can be sustained in the body of the user. The effect of releasing the (health-care component) and the stepwise release of the compound component material, thereby avoiding the interaction of the compound components.

(2)另一方面，藉由水溶性保護層12以及防潮保護層13包覆該靈樟芝精華核心11的結構方式，於服用所述的靈樟芝顆粒結構1之後，係能夠於服用者的體內達到持續釋放保健功效之成分以及分階釋放複方成分物質之效果，進而能夠避免複方成分交互作用。 (2) On the other hand, the structure of the Lingzhizhi essence core 11 is covered by the water-soluble protective layer 12 and the moisture-proof protective layer 13, and after taking the Lingzhizhi granule structure 1, the system can be used by the user. The body's ability to achieve sustained release of the health benefits and the effect of the stepwise release of the compound ingredients, thereby avoiding the interaction of the compound ingredients.

必須加以強調的是，上述之詳細說明係針對本新型可行實施例之具體說明，惟該實施例並非用以限制本新型之專利範圍，凡未脫離本新型技藝精神所為之等效實施或變更，均應包含於本案之專利範圍中。 It is to be understood that the foregoing detailed description of the preferred embodiments of the present invention is not intended to limit the scope of the invention, Both should be included in the scope of the patent in this case.

1‧‧‧靈樟芝顆粒結構 1‧‧‧ Lingzhizhi particle structure

11‧‧‧靈樟芝精華核心 11‧‧‧ Lingzhizhi essence core

12‧‧‧水溶性保護層 12‧‧‧Water-soluble protective layer

13‧‧‧防潮保護層 13‧‧‧ moisture protection layer

Claims (9)

一種靈樟芝顆粒結構，係包括：一靈樟芝精華核心，其於所述靈樟芝顆粒結構之中的重量百分比係介於12.8wt%至55.7wt%之間；一水溶性保護層，用以包覆於該靈樟芝精華核心；並且，該水溶性保護層於所述靈樟芝顆粒結構之中的重量百分比係介於40wt%至60wt%之間；以及一防潮保護層，用以包覆於該水溶性保護層；並且，該防潮保護層於所述靈樟芝顆粒結構之中的重量百分比係介於40wt%至60wt%之間。 The structure of the Lingzhizhi granules comprises: a core of Lingzhizhi extract, wherein the weight percentage of the Lingzhizhi granule structure is between 12.8 wt% and 55.7 wt%; a water-soluble protective layer, For coating the core of the Lingzhi extract; and the weight percentage of the water-soluble protective layer in the structure of the Lingzhi granule is between 40% and 60% by weight; and a moisture-proof protective layer, And coating the water-soluble protective layer; and the moisture percentage of the moisture-proof protective layer in the structure of the Lingzhi granule is between 40% by weight and 60% by weight. 如申請專利範圍第1項所述之靈樟芝顆粒結構，其中，該水溶性保護層係選自於包含於下列群組中的任一者：聚乙二醇(polyethylene glycol,PEG)、聚乙烯吡咯烷酮(polyvinylpyrrolidone,PVP)、聚氧乙烯單硬脂酸脂(polyoxyethylene monostearate,S40)、硬脂酸鈉、甘油、明膠、尿素、泊洛沙姆(poloxamer)、與上述任兩者或兩者以上的混合物。 The ganoderma lucidum particle structure according to claim 1, wherein the water-soluble protective layer is selected from the group consisting of polyethylene glycol (PEG), poly Polypyridrolidone (PVP), polyoxyethylene monostearate (S40), sodium stearate, glycerin, gelatin, urea, poloxamer, or both The above mixture. 如申請專利範圍第1項所述之靈樟芝顆粒結構，其中，該防潮保護層係為一增塑性基質，且該增塑性基質係選自於包含於下列群組中的任一者：預膠化澱粉、羧甲基澱粉、甲基纖維素、羧甲基纖維素鈉、羥丙基甲基纖維素、***膠、海藻酸、糊精、環糊精、瓊脂、乳糖、與上述任兩者或兩者以上的混合物。 The Lingzhizhi granule structure according to Item 1, wherein the moisture-proof protective layer is a plasticizing matrix, and the plasticizing matrix is selected from any one of the following groups: Gelatinized starch, carboxymethyl starch, methylcellulose, sodium carboxymethylcellulose, hydroxypropylmethylcellulose, gum arabic, alginic acid, dextrin, cyclodextrin, agar, lactose, and any of the above Or a mixture of two or more. 如申請專利範圍第1項所述之靈樟芝顆粒結構，其中，該靈樟芝精華核心係包含一牛樟芝萃出物與一靈芝萃出物。 For example, the Lingzhizhi granule structure described in claim 1 is characterized in that the core of the Lingzhizhi extract contains a extract of Antrodia camphorata and a extract of Ganoderma lucidum. 如申請專利範圍第4項所述之靈樟芝顆粒結構，其中，該靈樟芝精華核心更包含至少一輔酵素。 For example, the Lingzhizhi granule structure described in claim 4, wherein the core of the lingzhi essence further comprises at least one coenzyme. 如申請專利範圍第4項所述之靈樟芝顆粒結構，其中，所述靈樟芝顆粒結構為一靈樟芝滴丸，且該靈樟芝具有一滴丸大小與一滴丸重量；其中，該滴丸大小係介於2.0mm至3.5mm之間，且該滴丸重量係介於18毫克/顆至25毫克/顆之間。 The Lingzhizhi granule structure according to Item 4 of the patent application, wherein the Lingzhizhi granule structure is a Lingzhizhi drop pill, and the Lingzhizhi has a drop size and a drop weight; wherein The dropping size is between 2.0 mm and 3.5 mm, and the dropping weight is between 18 mg/25 mg/kg. 如申請專利範圍第4項所述之靈樟芝顆粒結構，其中，該牛樟芝萃出物係至少包含三萜類化合物(triterpenoids)與腺苷(Adenosine)。 The Lingzhizhi granule structure according to the fourth aspect of the invention, wherein the extract of the Antrodia camphorata comprises at least triterpenoids and adenosine. 如申請專利範圍第4項所述之靈樟芝顆粒結構，其中，該靈芝萃出物係至少包含多醣體(polysaccharide)。 The ganoderma lucidum granule structure according to claim 4, wherein the ganoderma lucidum extracting system comprises at least a polysaccharide. 如申請專利範圍第5項所述之靈樟芝顆粒結構，其中，該至少一輔酵素為一維生素B群或一輔酶Q10。 The lingzhi granule structure according to claim 5, wherein the at least one coenzyme is a vitamin B group or a coenzyme Q10.